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Introduction 
 It is estimated that currently 8.3% of the U.S. population has diabetes, with nearly 2 
million new cases each year (American Diabetes Association, 2013). The total cost of 
treating diagnosed diabetes is $245 billion annually (American Diabetes Association 2013), 
with no cure known. As type II Diabetes progresses, B-cell function decreases and 
apoptosis increases (Butler et al., 2003). Human Islet Amyloid Polypeptide (hIAPP) has 
been found to form plaques in the islets of type II Diabetes patients (Kahn et al., 1999), and 
hIAPP has been shown to be toxic to the B-cells, causing apoptosis (Lorenzo et al., 1994). 
 IAPP is a native protein in the body that regulates blood sugar by slowing gastric 
emptying and promoting satiety (Westermark et al., 2011). As B-cells die, the remaining 
islets cannot keep up with insulin release, causing or contributing to hyperglycemia. Zinc 
has been shown to slow the aggregation of hIAPP likely due to an interaction with His18 of 
the protein (Brender et al., 2010). Cu(II) (Ward et al., 2007, Brender et al., 2010) and gold 
complexes (He et al., 2015) have also been demonstrated to potentially inhibit the 
aggregation of hIAPP in vitro. However, complete studies should look at atomic force 
microscopy (AFM) pictures to exclude the possibility of interference of dye-fibril binding 
(Hudson et al., 2009). 
 This study set out to test the potential for inhibition of hIAPP aggregation by 
incubation with metal cations. Fluorimetry using Thioflavin T (ThT), which binds to pleated 
B-sheets in amyloid fibrils (Groenning et al., 2007), was used as a preliminary test. AFM, 
which scans slides to show fibril structure, was used to confirm positive results for ThT. 
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Materials and Methods 
Preparation of hIAPP solutions 
 Human hIAPP (hIAPP) was ordered from _________ (batch no.) and __________ (batch 
no.) suspended in hexafluoroisopropanol and frozen at -80 C until each run. At the 
beginningof each ThT assay, 375 uL (1st batch) or 325 uL (2nd batch) of hIAPP was added to 
glass culture tubes and the solvent evaporated off in a Speed-Vac (Thermofischer Scientific 
DNA120) before metal solutions were added. 
Preparation of metal solutions 
 The appropriate amount of metal compound to achieve a concentration of 10 mM 
was added in a solution of 20 mM TRIS (pH=7.4). 
Thioflavin T assays 
 15 uL metal solution was added to the hIAPP in culture tubes with 135 uL TRIS 
buffer; 150 uL TRIS buffer was used each time as a control. The samples were incubated in 
a shaker (New Brunswick Scientific Innova 4000) and samples were removed to test ThT 
fluorescence. 17 uL metal-IAPP solution was added with 663 uL of 75 uM ThT to 
fluorescence cuvettes; the fluorescence was measured in a fluorescence spectrophotometer 
(Hitachi F-7000) with an excitation wavelength of 450 nm; ThT fluorescence was measured 
at 488 nm. A t-test was used to determine whether metals significantly lowered ThT 
fluorescence. 
Atomic force microscopy 
 Metals that successfully reduced ThT fluorescence compared to their respective 
controls were run on an atomic force microscope to confirm the absence of fibrils.  
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Results 
Thioflavin T Assays 
 Cu(II) and Ni(II) were the only two metals to have significantly lower Thioflavin T 
concentrations (t-test: p=0.000278, dof=3; p=0.049, dof=3, respectively; figs. 1,2).  
 
When considering all metals, Cu(II), Ni(II), Sn(II), Zn(II), and Co(II) all showed 
promising Thioflavin T results when compared to their respective controls (fig. 3). 
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Figure 1: Cu(II) significantly inhibits ThT fluorescence; Zn(II) may 
inhibit; Mg(II) does not. 
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Figure 2: Ni(II) significantly inhibits ThT fluorescence; Co(II) likely 
does not. 
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Figure 3: Max ThT fluorescence of various 10mM metal treatments (mostly divalent chlorides) as a percentage of their respective 
controls. Cu(II), Zn(II) Ni(II), Co(II), Sn(II) appear to inhibit ThT fluorescence.  
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AFM 
 All metals appeared to have more 
aggregated hIAPP than the control (Fig. 4, panel 1), 
especially Cu and Zn (Fig. 4, panels 2 and 3). Zn 
and Cu displayed the thickest fibers of hIAPP; Ni 
had dense but smaller fibrils (Fig. 4, panel 4) and 
Sn had thicker fibrils that were less dense (Fig. 4, 
panel 5).  
  
 
Discussion 
 This study set out to learn whether metal cations would be able to prevent the 
aggregation of hIAPP. The mechanism detailing Zn(II) inhibition of hIAPP aggregation has 
previously been elucidated (Brender et al., 2010), and other studies have shown other 
divalent cations such as Cu(II) similarly inhibited Thioflavin T fluorescence. 19 positively 
charged species, including 13 metal dications and 5 metal monocations were tested, with 5 
of the dications lowering Thioflavin T fluorescence compared to their hIAPP controls, 
including Zn(II). After examining the solutions of Zn(II), Cu(II), Ni(II), and Sn(II) under 
AFM, none appeared to decrease the thickness and density of fibril growth. 
 The common disagreement between the Thioflavin T fluorescence and AFM results 
may be due to interference by the metal with the dye binding hIAPP. In these instances, a 
low ThT fluorescence value would suggest the metal inhibited hIAPP aggregation when it 
really interfered with ThT binding aggregated IAPP. This has been shown to occur with 
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polyphenolics (Hudson et al., 2009), but not yet with metals. The metals tested herein 
should therefore be tested for their ThT-binding properties. Additionally, if the metals were 
to promote aggregation as Zn and Cu have been shown to do with Aβ42 (Noy et al., 2008), 
fluorescence would decrease as the dye would not be able to bind as great a surface area. 
This illustrates the importance of AFM or Transmission Electron Microscopy (TEM) as a 
confirmatory test for suspected hIAPP aggregation inhibitors. 
The discrepancy found between literature findings and the findings of this 
experiment may be explained by the metal ion concentration hIAPP was treated with, 
which in this experiment was 10 mM. Similar experiments used concentrations of 0.4 uM 
for (Ward et al., 2008) or 10-25 uM, more similar to physiological conditions in the Beta 
cells (Brender et al., 2010). In fact, Zn concentrations higher than 500 uM stop increasing 
the lag time (time before which hIAPP aggregates) and increase the elongation rate of 
fibrils, suggesting the mechanism for Zn interaction with hIAPP is different at lower and 
higher An concentrations (Brender et al., 2010). Since Cu has the same hypothesized His-18 
binding mechanism as Zn, only stronger (Brender et al., 2010), it is possible the same trend 
is true for Cu. The only metal tested at different concentrations was Sn(II), as the chloride 
salt wasn’t completely soluble at 10 mM; as such, 10 mM (unfiltered and filtered), 1 mM, 
and 0.5 mM concentration solutions were prepared and tested. However, the higher 
concentration supersaturated solution seemed to decrease ThT fluorescence best, 
indicating the trend for Zn is not true for at least Sn. This is possibly due to different 
mechanisms of interaction with hIAPP. Future work should attempt to discover optimal 
inhibitory concentrations for metal cations. 
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